Journal of advanced research · 2026
Host-targeted apple pectic oligosaccharides repair intestinal barrier in colitis via HSP90β/miRNA/CORO2A axis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fan Xiangqi, Xiao Xiangjun, Tan Dayan, Yu Bing, Chen Daiwen, He Jun, Luo Junqiu, Luo Yuheng, Yan Hui, Wang Jianping, Wu Aimin, Wang Quyuan, Wang Huifen, Mao Xiangbing
Аннотация
INTRODUCTION: While functional oligosaccharides alleviate inflammatory bowel disease (IBD), their mechanisms conventionally attributed to gut microbiota modulation. The direct, host-targeted regulatory pathways of apple pectic oligosaccharides (APOS) remain elusive.
OBJECTIVES: This study aimed to elucidate the host-directed parallel mechanism by which APOS restores intestinal epithelial barrier integrity and immune homeostasis during colitis.
METHODS: We integrated multi-omics analysis, biophysical binding validation, and a dextran sulfate sodium (DSS)-induced rat colitis model. Mechanistic dependency was validated via in vivo miRNA rescue and in vitro (IEC18 and human Caco-2) models using dual-luciferase assays and bidirectional genetic manipulation.
RESULTS: APOS (200 mg/kg) significantly ameliorated colitis severity. Mechanistically, APOS directly bound to the N-terminal pocket of membrane HSP90β on intestinal epithelial cells. This interaction inhibited the release of miR-148a-5p and miR-216a-3p, thereby de-repressing their shared downstream target, the cytoskeletal regulator CORO2A. CORO2A restoration re-anchored junctional networks (ZO-1, AJAP1 and GJA1) and suppressed Th1/Th17-driven cytokine storms. Crucially, exogenous miRNA supplementation in vivo completely abolished APOS-mediated barrier protection despite maintaining a restored microbiome, confirming the indispensable role of this host-directed pathway.
CONCLUSION: Operating synergistically with microbial modulation, APOS functions as a highly potent (Human Equivalent Dose 11.35 mg/kg), host-directed therapeutic. By engaging the HSP90β/miRNA/CORO2A axis to rebuild the physical defense line, this study conceptualizes a novel framework for precision nutritional intervention in IBD.
OBJECTIVES: This study aimed to elucidate the host-directed parallel mechanism by which APOS restores intestinal epithelial barrier integrity and immune homeostasis during colitis.
METHODS: We integrated multi-omics analysis, biophysical binding validation, and a dextran sulfate sodium (DSS)-induced rat colitis model. Mechanistic dependency was validated via in vivo miRNA rescue and in vitro (IEC18 and human Caco-2) models using dual-luciferase assays and bidirectional genetic manipulation.
RESULTS: APOS (200 mg/kg) significantly ameliorated colitis severity. Mechanistically, APOS directly bound to the N-terminal pocket of membrane HSP90β on intestinal epithelial cells. This interaction inhibited the release of miR-148a-5p and miR-216a-3p, thereby de-repressing their shared downstream target, the cytoskeletal regulator CORO2A. CORO2A restoration re-anchored junctional networks (ZO-1, AJAP1 and GJA1) and suppressed Th1/Th17-driven cytokine storms. Crucially, exogenous miRNA supplementation in vivo completely abolished APOS-mediated barrier protection despite maintaining a restored microbiome, confirming the indispensable role of this host-directed pathway.
CONCLUSION: Operating synergistically with microbial modulation, APOS functions as a highly potent (Human Equivalent Dose 11.35 mg/kg), host-directed therapeutic. By engaging the HSP90β/miRNA/CORO2A axis to rebuild the physical defense line, this study conceptualizes a novel framework for precision nutritional intervention in IBD.